Contribution of regulatory T cells to immunosuppression and disease progression in multiple myeloma patients

Por Raja, Karthick Raja Muthu, Hajek, Roman
Publicado em 2013

Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma

Por Jelinek, Tomas, Paiva, Bruno, Hajek, Roman
Publicado no Front Immunol (2018)

TGF-β – an excellent servant but a bad master

Por Kubiczkova, Lenka, Sedlarikova, Lenka, Hajek, Roman, Sevcikova, Sabina
Publicado em 2012

Design and rationale of FOCUS (PX-171-011): A randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory mult...

Por Hájek, Roman, Bryce, Richard, Ro, Sunhee, Klencke, Barbara, Ludwig, Heinz
Publicado em 2012

Proteasome inhibitors – molecular basis and current perspectives in multiple myeloma

Por Kubiczkova, Lenka, Pour, Ludek, Sedlarikova, Lenka, Hajek, Roman, Sevcikova, Sabina
Publicado no J Cell Mol Med (2014)

PD‐1/PD‐L1 inhibitors in haematological malignancies: update 2017

Por Jelinek, Tomas, Mihalyova, Jana, Kascak, Michal, Duras, Juraj, Hajek, Roman
Publicado no Immunology (2017)

Long Non-Coding RNAs in Multiple Myeloma

Por Butova, Romana, Vychytilova-Faltejskova, Petra, Souckova, Adela, Sevcikova, Sabina, Hajek, Roman
Publicado no Noncoding RNA (2019)

Increased T Regulatory Cells Are Associated with Adverse Clinical Features and Predict Progression in Multiple Myeloma

Por Muthu Raja, Karthick Raja, Rihova, Lucie, Zahradova, Lenka, Klincova, Maria, Penka, Miroslav, Hajek, Roman
Publicado em 2012

High levels of FLT3-ligand in bone marrow and peripheral blood of patients with advanced multiple myeloma

Por Steiner, Normann, Hajek, Roman, Sevcikova, Sabina, Borjan, Bojana, Jöhrer, Karin, Göbel, Georg, Untergasser, Gerold, Gunsilius, Eberhard
Publicado no PLoS One (2017)

Functionally Suppressive CD8 T Regulatory Cells Are Increased in Patients with Multiple Myeloma: A Cause for Immune Impairment

Por Muthu Raja, Karthick Raja, Kubiczkova, Lenka, Rihova, Lucie, Piskacek, Martin, Vsianska, Pavla, Hezova, Renata, Pour, Ludek, Hajek, Roman
Publicado em 2012

MicroRNAs in urine are not biomarkers of multiple myeloma

Por Sedlaříková, Lenka, Bešše, Lenka, Novosadová, Soňa, Kubaczková, Veronika, Radová, Lenka, Staník, Michal, Krejčí, Marta, Hájek, Roman, Ševčíková, Sabina
Publicado no J Negat Results Biomed (2015)

Centrosome associated genes pattern for risk sub-stratification in multiple myeloma

Por Kryukov, Fedor, Nemec, Pavel, Radova, Lenka, Kryukova, Elena, Okubote, Samuel, Minarik, Jiri, Stefanikova, Zdena, Pour, Ludek, Hajek, Roman
Publicado no J Transl Med (2016)

Expression and release of glucose-regulated protein-78 (GRP78) in multiple myeloma

Por Steiner, Normann, Borjan, Bojana, Hajek, Roman, Jöhrer, Karin, Göbel, Georg, Willenbacher, Wolfgang, Kern, Johann, Gunsilius, Eberhard, Untergasser, Gerold
Publicado no Oncotarget (2017)

The metabolomic plasma profile of myeloma patients is considerably different from healthy subjects and reveals potential new therapeutic targets

Por Steiner, Normann, Müller, Udo, Hajek, Roman, Sevcikova, Sabina, Borjan, Bojana, Jöhrer, Karin, Göbel, Georg, Pircher, Andreas, Gunsilius, Eberhard
Publicado no PLoS One (2018)

A Bird’s-Eye View of Cell Sources for Cell-Based Therapies in Blood Cancers

Por Motais, Benjamin, Charvátová, Sandra, Hrdinka, Matouš, Šimíček, Michal, Jelínek, Tomáš, Ševčíková, Tereza, Kořístek, Zdeněk, Hájek, Roman, Bagó, Juli R.
Publicado no Cancers (Basel) (2020)

Methodology of a Novel Risk Stratification Algorithm for Patients with Multiple Myeloma in the Relapsed Setting

Por Bouwmeester, Walter, Briggs, Andrew, van Hout, Ben, Hájek, Roman, Gonzalez-McQuire, Sebastian, Campioni, Marco, DeCosta, Lucy, Brozova, Lucie
Publicado no Oncol Ther (2019)

Intercellular Mitochondrial Transfer in the Tumor Microenvironment

Por Sahinbegovic, Hana, Jelinek, Tomas, Hrdinka, Matous, Bago, Juli R., Turi, Marcello, Sevcikova, Tereza, Kurtovic-Kozaric, Amina, Hajek, Roman, Simicek, Michal
Publicado no Cancers (Basel) (2020)

Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or...

Por Dimopoulos, Meletios A., Delforge, Michel, Hájek, Roman, Kropff, Martin, Petrucci, Maria T., Lewis, Philip, Nixon, Annabel, Zhang, Jingshan, Mei, Jay, Palumbo, Antonio
Publicado em 2013

Novel risk stratification algorithm for estimating the risk of death in patients with relapsed multiple myeloma: external validation in a retrospective chart review

Por Hájek, Roman, Gonzalez-McQuire, Sebastian, Szabo, Zsolt, Delforge, Michel, DeCosta, Lucy, Raab, Marc S, Bouwmeester, Walter, Campioni, Marco, Briggs, Andrew
Publicado no BMJ Open (2020)

Clinical implication of centrosome amplification and expression of centrosomal functional genes in multiple myeloma

Por Dementyeva, Elena, Kryukov, Fedor, Kubiczkova, Lenka, Nemec, Pavel, Sevcikova, Sabina, Ihnatova, Ivana, Jarkovsky, Jiri, Minarik, Jiri, Stefanikova, Zdena, Kuglik, Petr, Hajek, Roman
Publicado em 2013